These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 16323128)

  • 1. PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trial.
    Keller MJ; Zerhouni-Layachi B; Cheshenko N; John M; Hogarty K; Kasowitz A; Goldberg CL; Wallenstein S; Profy AT; Klotman ME; Herold BC
    J Infect Dis; 2006 Jan; 193(1):27-35. PubMed ID: 16323128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PRO 2000 elicits a decline in genital tract immune mediators without compromising intrinsic antimicrobial activity.
    Keller MJ; Guzman E; Hazrati E; Kasowitz A; Cheshenko N; Wallenstein S; Cole AL; Cole AM; Profy AT; Wira CR; Hogarty K; Herold BC
    AIDS; 2007 Feb; 21(4):467-76. PubMed ID: 17301565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cervicovaginal secretions contribute to innate resistance to herpes simplex virus infection.
    John M; Keller MJ; Fam EH; Cheshenko N; Hogarty K; Kasowitz A; Wallenstein S; Carlucci MJ; Tuyama AC; Lu W; Klotman ME; Lehrer RI; Herold BC
    J Infect Dis; 2005 Nov; 192(10):1731-40. PubMed ID: 16235171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of cervicovaginal cytokine levels following exposure to microbicide Nisin gel in rabbits.
    Aranha CC; Gupta SM; Reddy KV
    Cytokine; 2008 Jul; 43(1):63-70. PubMed ID: 18513989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial.
    Zuckerman RA; Lucchetti A; Whittington WL; Sanchez J; Coombs RW; Zuñiga R; Magaret AS; Wald A; Corey L; Celum C
    J Infect Dis; 2007 Nov; 196(10):1500-8. PubMed ID: 18008230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maternal herpes simplex virus type 2 coinfection increases the risk of perinatal HIV transmission: possibility to further decrease transmission?
    Bollen LJ; Whitehead SJ; Mock PA; Leelawiwat W; Asavapiriyanont S; Chalermchockchareonkit A; Vanprapar N; Chotpitayasunondh T; McNicholl JM; Tappero JW; Shaffer N; Chuachoowong R
    AIDS; 2008 Jun; 22(10):1169-76. PubMed ID: 18525263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amphipathic DNA polymers are candidate vaginal microbicides and block herpes simplex virus binding, entry and viral gene expression.
    Guzman EM; Cheshenko N; Shende V; Keller MJ; Goyette N; Juteau JM; Boivin G; Vaillant A; Herold BC
    Antivir Ther; 2007; 12(8):1147-56. PubMed ID: 18240855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I study of a novel potential intravaginal microbicide, PRO 2000, in healthy sexually inactive women.
    Van Damme L; Wright A; Depraetere K; Rosenstein I; Vandersmissen V; Poulter L; McKinlay M; Van Dyck E; Weber J; Profy A; Laga M; Kitchen V
    Sex Transm Infect; 2000 Apr; 76(2):126-30. PubMed ID: 10858715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection.
    Palliser D; Chowdhury D; Wang QY; Lee SJ; Bronson RT; Knipe DM; Lieberman J
    Nature; 2006 Jan; 439(7072):89-94. PubMed ID: 16306938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ACIDFORM inactivates herpes simplex virus and prevents genital herpes in a mouse model: optimal candidate for microbicide combinations.
    Tuyama AC; Cheshenko N; Carlucci MJ; Li JH; Goldberg CL; Waller DP; Anderson RA; Profy AT; Klotman ME; Keller MJ; Herold BC
    J Infect Dis; 2006 Sep; 194(6):795-803. PubMed ID: 16941346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of association between human immunodeficiency virus type 1 antibody in cervicovaginal lavage fluid and plasma and perinatal transmission, in Thailand.
    Chuachoowong R; Shaffer N; VanCott TC; Chaisilwattana P; Siriwasin W; Waranawat N; Vanprapar N; Young NL; Mastro TD; Lambert JS; Robb ML
    J Infect Dis; 2000 Jun; 181(6):1957-63. PubMed ID: 10837175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-course antenatal zidovudine reduces both cervicovaginal human immunodeficiency virus type 1 RNA levels and risk of perinatal transmission. Bangkok Collaborative Perinatal HIV Transmission Study Group.
    Chuachoowong R; Shaffer N; Siriwasin W; Chaisilwattana P; Young NL; Mock PA; Chearskul S; Waranawat N; Chaowanachan T; Karon J; Simonds RJ; Mastro TD
    J Infect Dis; 2000 Jan; 181(1):99-106. PubMed ID: 10608756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection, quantification and genotyping of Herpes Simplex Virus in cervicovaginal secretions by real-time PCR: a cross sectional survey.
    Aryee EA; Bailey RL; Natividad-Sancho A; Kaye S; Holland MJ
    Virol J; 2005 Aug; 2():61. PubMed ID: 16095535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaginal gel may prevent herpes transmission.
    AIDS Patient Care STDS; 2005 May; 19(5):351. PubMed ID: 15948277
    [No Abstract]   [Full Text] [Related]  

  • 15. Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy, HIV-negative women.
    Nel AM; Coplan P; van de Wijgert JH; Kapiga SH; von Mollendorf C; Geubbels E; Vyankandondera J; Rees HV; Masenga G; Kiwelu I; Moyes J; Smythe SC
    AIDS; 2009 Jul; 23(12):1531-8. PubMed ID: 19550287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Vaginal Acquisition and Dissemination of HIV-1 Infection in a Novel Transgenic Mouse Model Is Facilitated by Coinfection with Herpes Simplex Virus 2 and Is Inhibited by Microbicide Treatment.
    Seay K; Khajoueinejad N; Zheng JH; Kiser P; Ochsenbauer C; Kappes JC; Herold B; Goldstein H
    J Virol; 2015 Sep; 89(18):9559-70. PubMed ID: 26157126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postcoital bioavailability and antiviral activity of 0.5% PRO 2000 gel: implications for future microbicide clinical trials.
    Keller MJ; Mesquita PM; Torres NM; Cho S; Shust G; Madan RP; Cohen HW; Petrie J; Ford T; Soto-Torres L; Profy AT; Herold BC
    PLoS One; 2010 Jan; 5(1):e8781. PubMed ID: 20107502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential effect of HIV type 1 antiretroviral and herpes simplex virus type 2 antiviral therapy on transmission and acquisition of HIV type 1 infection.
    Celum CL; Robinson NJ; Cohen MS
    J Infect Dis; 2005 Feb; 191 Suppl 1():S107-14. PubMed ID: 15627220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of menopause on the innate antiviral activity of cervicovaginal lavage.
    Chappell CA; Isaacs CE; Xu W; Meyn LA; Uranker K; Dezzutti CS; Moncla BJ; Hillier SL
    Am J Obstet Gynecol; 2015 Aug; 213(2):204.e1-6. PubMed ID: 25818668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human immunodeficiency virus in plasma and cervicovaginal secretions in Filipino women.
    Natividad-Villanueva GU; Santiago E; Manalastas RM; Brown HW; Ingersoll J; Caliendo AM; Mayer KH; Cu-Uvin S
    Int J STD AIDS; 2003 Dec; 14(12):826-9. PubMed ID: 14678591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.